熱門資訊> 正文

Cybin报告第一季度业绩

2026-08-14 19:31

Intra-Cellular Therapies(ITCI) 0

Cybin press release (HELP): Q1 Net loss was $47.8 million for the quarter ended June 30, 2026, compared to a net loss of $24.6 million in the same period last year.
Cash totaled $166.4 million as of June 30, 2026.
Cash-based operating expenses consisting of research, general, and administrative costs totaled $37.5 million for the quarter ended June 30, 2026, compared to $23.9 million, in the same period last year.

More on Cybin

Helus Pharma: APPROACHing Inflection: Pivotal Readout Sets Up Asymmetric Upside
Cybin: A Speculative Bet On Their Pivotal Depression Readout
Cybin continues rally following CEO appointment, up another 13%
Helus Pharma names ex-Intra-Cellular executive Michael Halstead as CEO
Seeking Alpha’s Quant Rating on Cybin

推薦文章

風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。